Insulin glargine (Basaglar) vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin glargine (Basaglar)insulin icodec
HbA1c, change-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
-0.8% vs -0.6%vs Insulin Glarginewk 26 · n 204NCT06340854
11 other results
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.7% vs -1.3% wk 52 · n 542 · Phase 3 · primary NCT04760626
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)1.6 vs 1.9vs Lantuswk 16 · n 370NCT01421459
7 other results
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 1.9 vs 2.2 wk 24 · n 370 · Phase 3 · secondary NCT01421459
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
2.0 vs 0.6vs Insulin Glarginewk 26 · n 204NCT06340854
10 other results
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 2.3 vs 1.8 wk 52 · n 492 · Phase 3 · secondary NCT04460885
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
HbA1c below 7%43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010—Not posted · NCT05013229
Fasting plasma glucose, change—Not reported-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not reported—Not posted · NCT05013229

HbA1c, change

Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
insulin icodec
-0.8% vs -0.6%vs Insulin Glarginewk 26 · n 204NCT06340854
11 other results
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.7% vs -1.3% wk 52 · n 542 · Phase 3 · primary NCT04760626
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

Insulin glargine (Basaglar)
1.6 vs 1.9vs Lantuswk 16 · n 370NCT01421459
7 other results
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 1.9 vs 2.2 wk 24 · n 370 · Phase 3 · secondary NCT01421459
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
insulin icodec
2.0 vs 0.6vs Insulin Glarginewk 26 · n 204NCT06340854
10 other results
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 2.3 vs 1.8 wk 52 · n 492 · Phase 3 · secondary NCT04460885
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657

HbA1c below 7%

Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

Insulin glargine (Basaglar)
—Not reported
insulin icodec
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

Insulin glargine (Basaglar)
—Not reported
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Insulin glargine (Basaglar): 6 of 6 rows · insulin icodec: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin glargine (Basaglar)
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.86% (n=259) @ 24wka,b,c,d
NCT04153981 · Phase 4 · registry result, not featured evidence
-1.23% (n=91) @ 52wka,b,c,d
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Weight
absolute change · kg
No placebo or comparator arm
-0.5 kg @ 24wka,b,c,d
NCT04153981 · Phase 4 · registry result, not featured evidence
-3.85 kg @ 52wka,b,c,d
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
11.9%e
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.6%e
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
—f
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
4%e
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
f
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 24 weeks.
  5. ePopulation comparability has not been reviewed for 1 of these studies.
  6. fPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Basaglar)

HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

insulin icodec

Time in Range 71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wk
absolute value · percentage points
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
19.94% (n=202) vs 11.04% (n=198) Insulin Glargine @ 26wk
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
63.13% (n=238) vs 59.5% (n=239) Insulin Degludec @ 26wk
NCT04770532 · Phase 3
Fasting Plasma Glucose -3.35 vs -3.33 Insulin Glargine mmol/L @ 52wk
absolute change · mmol/L
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 9 more results
-3.01 vs -2.99 Insulin Degludec mmol/L @ 26wk
NCT04795531 · Phase 3
-1.58 vs -1.62 Insulin Degludec mmol/L @ 26wk
NCT04770532 · Phase 3
-1.75 vs -1.61 Insulin Glargine mmol/L @ 26wk
NCT04880850 · Phase 3
-0.83 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-0.69 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-3.2 vs -2.99 Insulin Glargine mmol/L @ 26wk
NCT03751657 · Phase 2 · registry result, not featured evidence
-2.23 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-2.42 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-3.01 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below Range 0.27 vs 0.21 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 26.86 vs 32.27 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
35.52 vs 39.71 Insulin Degludec % of time @ 26wk
NCT04770532 · Phase 3
30.47 vs 31.3 Insulin Glargine % of time @ 26wk
NCT04880850 · Phase 3
Time Above Range -20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wk
absolute value · percentage points
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 2 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
0 vs 0 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 53 vs 23 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3 53 vs 25 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time Below 54 mg/dL 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wk
absolute value · percentage points
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below 54 mg/dL 0.73 vs 0.61 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Basaglar)'s landscape · insulin icodec's landscape